Bradley Foster & Sargent Inc Crispr Therapeutics Ag Transaction History

Bradley Foster & Sargent Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $31,914 - $47,544	600 Added 21.81%	3,351 $210,000
Q4 2021 Mar 11, 2022	BUY	$70.09 - $111.29 $11,214 - $17,806	160 Added 6.18%	2,751 $208,000
Q3 2021 Nov 10, 2021	BUY	$110.2 - $156.64 $1,102 - $1,566	10 Added 0.39%	2,591 $290,000
Q2 2021 Aug 19, 2021	BUY	$100.84 - $161.89 $12,100 - $19,426	120 Added 4.88%	2,581 $418,000
Q1 2021 Apr 26, 2021	BUY	$110.72 - $210.04 $1,217 - $2,310	11 Added 0.45%	2,461 $300,000
Q4 2020 Feb 11, 2021	BUY	$79.67 - $173.23 $195,191 - $424,413	2,450 New	2,450 $375,000
Q4 2018 Jan 30, 2019	SELL	$22.73 - $42.34 $215,025 - $400,536	-9,460 Closed	0 $0
Q3 2018 Oct 31, 2018	BUY	$44.35 - $65.71 $419,551 - $621,616	9,460 New	9,460 $420,000
Q1 2018 May 07, 2018	SELL	$23.52 - $58.17 $276,712 - $684,370	-11,765 Closed	0 $0
Q4 2017 Feb 06, 2018	BUY	$16.95 - $23.48 $199,416 - $276,242	11,765	11,765 $276,000

485

57.5M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.12B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Bradley Foster & Sargent Inc, based on Form 13F filings with the SEC.

Stay updated on Bradley Foster & Sargent Inc with notifications on news.